PE20000240A1 - Uso de apomorfina para el tratamiento de las disfunciones sexuales femeninas - Google Patents

Uso de apomorfina para el tratamiento de las disfunciones sexuales femeninas

Info

Publication number
PE20000240A1
PE20000240A1 PE1999000067A PE00006799A PE20000240A1 PE 20000240 A1 PE20000240 A1 PE 20000240A1 PE 1999000067 A PE1999000067 A PE 1999000067A PE 00006799 A PE00006799 A PE 00006799A PE 20000240 A1 PE20000240 A1 PE 20000240A1
Authority
PE
Peru
Prior art keywords
apomorphine
treatment
female sexual
sexual dysfunctions
refers
Prior art date
Application number
PE1999000067A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of PE20000240A1 publication Critical patent/PE20000240A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

SE REFIERE AL USO DE APOMORFINA O UNA SAL DE ADICION ACIDA PARA MEJORAR LA FUNCION SEXUAL EN UNA MUJER, UTILIZANDOSE DE 2 A 12 MILIGRAMOS O DE 25 A 80 MICROGRAMOS POR KILOGRAMO. TAMBIEN SE REFIERE AL USO ADEMAS DE UNA ß-CICLODEXTRINA TAL COMO HIDROXIPROPILO DE ß-CICLODEXTRINA. LA APOMORFINA ES UN ANTAGONISTA DEL RECEPTOR DE DOPAMINA EN LA REGION DEL MESENCEFALO POR LO QUE PUEDE UTILIZARSE PARA INCREMENTAR EL FLUJO SANGUINEO INTRACLITORAL PRODUCIENDO ERECTOGENESIS CLITORAL E INCREMENTANDO EL FLUJO SANGUINEO DE LA PARED VAGINAL
PE1999000067A 1998-01-30 1999-01-29 Uso de apomorfina para el tratamiento de las disfunciones sexuales femeninas PE20000240A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
PE20000240A1 true PE20000240A1 (es) 2000-03-31

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000067A PE20000240A1 (es) 1998-01-30 1999-01-29 Uso de apomorfina para el tratamiento de las disfunciones sexuales femeninas

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
EP1089736A2 (en) * 1998-06-22 2001-04-11 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
AU2001255818A1 (en) 2000-04-07 2001-10-23 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
US6762202B2 (en) 2000-05-09 2004-07-13 Nitromed, Inc. Infrared thermography and methods of use
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
CN1486183A (zh) 2000-11-15 2004-03-31 ����ҽҩƷ���޹�˾ 使用阿朴吗啡治疗抗抑郁药引发的性功能障碍
WO2002041894A2 (en) * 2000-11-22 2002-05-30 Abbott Laboratories Selective dopamine d4 receptor agonists for treating sexual dysfunction
AR032556A1 (es) * 2001-02-08 2003-11-12 Pharmacia Corp Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
AU2003223304A1 (en) * 2002-03-19 2003-10-08 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
CA2522231A1 (en) * 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
CA2603649C (en) * 2005-04-08 2014-10-14 Ozpharma Pty Ltd Buccal delivery system
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US8349850B2 (en) 2006-03-28 2013-01-08 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
CA2832822A1 (en) 2011-04-10 2012-10-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
AU4312593A (en) * 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
KR100374924B1 (ko) * 1994-04-22 2003-07-22 퀸스 유니버시티 엣 킹스톤 남성발기기능장애를회복시키고진단하기위한설하용량형
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
BG64667B1 (bg) 2005-11-30
CN1250221C (zh) 2006-04-12
HUP0101268A3 (en) 2002-12-28
DZ2714A1 (fr) 2003-09-01
US6193992B1 (en) 2001-02-27
WO1999038467A1 (en) 1999-08-05
ZA99686B (en) 1999-07-28
PA8467801A1 (es) 2000-09-29
AU752928B2 (en) 2002-10-03
HK1040901A1 (en) 2002-06-28
HN1999000015A (es) 1999-08-23
NO20003845L (no) 2000-09-28
GT199900013A (es) 2001-07-20
HUP0101268A2 (hu) 2001-09-28
NO20003845D0 (no) 2000-07-27
IL137569A (en) 2006-08-01
MA26600A1 (fr) 2004-12-20
JP2002501875A (ja) 2002-01-22
PL342062A1 (en) 2001-05-21
EP1056419A1 (en) 2000-12-06
TR200002220T2 (tr) 2000-12-21
EP1056419A4 (en) 2007-05-02
NO319821B1 (no) 2005-09-19
CA2322289A1 (en) 1999-08-05
GC0000096A (en) 2005-06-29
TNSN99008A1 (fr) 2005-11-10
BR9908038A (pt) 2002-01-02
CR5959A (es) 1999-07-28
BG104715A (bg) 2001-02-28
JO2085B1 (en) 2000-05-21
US5945117A (en) 1999-08-31
NZ506597A (en) 2003-07-25
AR017976A1 (es) 2001-10-24
TW550069B (en) 2003-09-01
IL137569A0 (en) 2001-07-24
SK11362000A3 (sk) 2001-02-12
PL194350B1 (pl) 2007-05-31
MXPA00007447A (es) 2006-01-25
CN1313742A (zh) 2001-09-19
CO4970819A1 (es) 2000-11-07
UY25374A1 (es) 1999-09-27
HK1040901B (zh) 2006-11-24
AU2564499A (en) 1999-08-16
KR20010040477A (ko) 2001-05-15

Similar Documents

Publication Publication Date Title
PE20000240A1 (es) Uso de apomorfina para el tratamiento de las disfunciones sexuales femeninas
PE20010817A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
DE60115842D1 (de) Ventilanordnung
NO20044699L (no) Vaginalpleiesammensetning
UY27878A1 (es) Derivados de indolinfenilsulfonamida
ATE545407T1 (de) Pharmazeutische formulierung von apomorphin für die bukkale verabreichung
GB2456475A (en) Composition for the treatment of skin conditions
AU6569600A (en) Method for embellishing the shape of a human body by means of a cosmetic plaster
CL2008002466A1 (es) Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado.
DOP2002000481A (es) Derivados de acido acetico
MX2007013466A (es) Composicion cosmetica.
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
WO2001089538A3 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
AU2003280071A1 (en) Hydroxypyridinones for the local treatment of skin microcirculatory disorders
CN102552995A (zh) 人体润滑剂
ES2170726B1 (es) Procedimiento para la obtencion de un extracto aislado de la planta cyclamen europaeum l. y su utilizacion como agente terapeutico.
Dayakar et al. Elective tongue piercing: fad with fallout
CN1843312A (zh) 早泄阴茎套
CN2381318Y (zh) 足部按摩石
CN201840635U (zh) 刮痧灸疗器
FR2280707A2 (fr) Ghassoulite : savonnette de toilette, destinee au maintien de l'hygiene cutane
Rott Menorrhagia more common in phenprocoumon recipients
Macdonald Sodium laurilsulfate

Legal Events

Date Code Title Description
FC Refusal